Biotech's movers for the week of May 11th and a preview of the week ahead
REGENXBIO traded down on a key data release for its DMD therapy, which spotlights investor uncertainty about how new leadership at FDA will treat these kind of treatments. This news and more covering movers of the last week.
1 day ago
ASGCT 2026: Tenaya Therapeutics today presented interim clinical data for its gene therapy for patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 mutations
CEO Faraz Ali walks us through the data, which included six patients, and sets the table for a future update on a gene therapy program for hypertrophic cardiomyopathy that will be announced before the end of the quarter. Coverage brought to you by
2 days ago
ASGCT 2026: Aurion Biotech is developing an off the shelf cell therapy solution for Corneal endothelial disease, a type of blindness, where only donor transplants are currently available to some
Founder, CSO & CEO Arnaud Lacoste describes the treatment, which is derived from one donor and can treat up to 1,000 patients, and comes in a solution containing a rho-kinase inhibitor. It is currently in a U.S. pivotal study. Coverage brought to you by
2 days ago
.png){kind=logo}
